基因组变异对拉帕替尼治疗HER2阳性胃癌结局及治疗期间游离基因组景观的影响
该前瞻性研究评估拉帕替尼联合卡培他滨和奥沙利铂一线新辅助治疗初治HER2过表达晚期胃癌的疗效,并同步进行肿瘤组织免疫组化与NGS及血液cfDNA分析。结果显示总缓解率68.6%,CCNE1扩增与HER2靶向治疗无应答呈边缘统计学显著相关,高水平ERBB2扩增或血浆可检测ERBB2拷贝数扩增可预测应答,疾病进展时出现MYC、EGFR、FGFR2和MET扩增等新发基因组变异。
要点
- 拉帕替尼联合卡培他滨和奥沙利铂一线新辅助治疗HER2过表达晚期胃癌总缓解率达68.6%。
- 高水平ERBB2扩增(NGS)或血浆可检测ERBB2拷贝数扩增可预测拉帕替尼应答。
- CCNE1扩增在HER2+肿瘤中占40%,与无应答趋势相关(P=0.08)。
核心结论
- HER2+胃癌患者根据ERBB2之外的伴随基因组变异呈现不同应答,高水平ERBB2扩增或cfDNA可检测ERBB2扩增可作为患者筛选的正向预测指标,且靶向治疗期间肿瘤基因组变异发生显著变化。
研究设计与样本
- 前瞻性评估拉帕替尼联合卡培他滨和奥沙利铂作为初治HER2过表达晚期胃癌一线新辅助治疗的疗效。
- 平行生物标志物研究同步对肿瘤和血液样本进行免疫组化与下一代测序(NGS)。
主要发现
- 16例肿瘤标本NGS显示最常见的共现拷贝数变异为CCNE1扩增,存在于40%的HER2+肿瘤中。
- CCNE1扩增与HER2靶向治疗无应答的关系趋势 toward 统计学显著性(无应答者66.7% vs 应答者22.2%携带CCNE1扩增;P=0.08)。
- NGS显示高水平ERBB2扩增患者较低水平ERBB2扩增患者更可能应答(P=0.02)。
- cfDNA分析显示血浆可检测ERBB2拷贝数扩增可预测应答(应答率100%),血浆检测的基因组变异变化与拉帕替尼敏感性和/或耐药相关;疾病进展时cfDNA基因组随访显示出现MYC、EGFR、FGFR2和MET扩增等其他基因组异常。
临床怎么用
- 对HER2+胃癌患者,可考虑通过NGS评估ERBB2扩增水平及CCNE1等伴随变异,高水平ERBB2扩增或血浆可检测ERBB2扩增提示更可能从拉帕替尼联合治疗中获益。
- 治疗期间及疾病进展时可通过cfDNA动态监测基因组变异变化,以辅助判断敏感性与耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To identify predictive markers for responders in lapatinib-treated patients and to demonstrate molecular changes during lapatinib treatment via cell-free genomics. PATIENTS AND METHODS: We prospectively evaluated the efficacy of combining lapatinib with capecitabine and oxaliplatin as first line neoadjuvant therapy in patients with previously untreated, HER2-overexpressing advanced gastric cancer. A parallel biomarker study was conducted by simultaneously performing immunohistochemistry and next-generation sequencing (NGS) with tumor and blood samples. RESULTS: Complete response was confirmed in 7/32 patients (21.8%), 2 of whom received radical surgery with pathologic-confirmed complete response. Fifteen partial responses (46.8%) were observed, resulting in a 68.6% overall response rate. NGS of the 16 tumor specimens demonstrated that the most common co-occurring copy number alteration was CCNE1 amplification, which was present in 40% of HER2+ tumors. The relationship between CCNE1 amplification and lack of response to HER2-targeted therapy trended toward statistical significance (66.7% of non-responders versus 22.2% of responders harbored CCNE1 amplification; P = 0.08). Patients with high level ERBB2 amplification by NGS were more likely to respond to therapy, compared with patients with low level ERBB2 amplification (P = 0.02). Analysis of cfDNA showed that detectable ERBB2 copy number amplification in plasma was predictive to the response (100%, response rate) and changes in plasma-detected genomic alterations were associated with lapatinib sensitivity and/or resistance. The follow-up cfDNA genomics at disease progression demonstrated that there are emergences of other genomic aberrations such as MYC, EGFR, FGFR2 and MET amplifications. CONCLUSIONS: The present study showed that HER2+ GC patients respond differently according to concomitant genomic aberrations beyond ERBB2, high ERBB2 amplification by NGS or cfDNA can be a positive predictor for patient selection, and tumor genomic alterations change significantly during targeted agent therapy.
引用
- Kim ST, Banks KC, Pectasides E, et al. Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients. Ann Oncol. 2018. PMID: 29409051. doi:10.1093/annonc/mdy034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。